跳至主要内容
临床试验/CTRI/2022/02/040562
CTRI/2022/02/040562尚未招募3 期

Evaluating clinical efficacy of Guduchyadi compound in the management of Mild to Moderate COVID-19 cases along with comorbid conditions as stand alone and add on medicine. - NA

All India Institute Of Ayurveda0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Newly diagnosed COVID-19 confirmed by RT-PCR.
  • 2.Mild to Moderate COVID-19 infection.
  • 3.Comorbid conditions (HTN, Diabetes, Metabolic
  • 4.Willingness and ability to comply with trial and follow-up
  • procedures.
  • 5.Ability to understand the nature of this trial and give written informed consent.

排除标准

  • 1.Patients with severe and critical infection will be excluded.
  • 2.Patients with severe COVID-19 infection
  • 3.Patients with respiratory failure who need mechanical ventilation
  • 4.Patients who cannot take drug orally
  • 5.Inability or unwillingness to comply with study and/or follow-up procedures
  • 6.Enrolled in other researches for treatment of COVID-19 infection

研究者

相似试验